BioMarin to acquire Inozyme Pharma for US$270M to advance ENPP1 therapy

USA—BioMarin Pharmaceutical has announced a definitive agreement to acquire Inozyme Pharma in an all-cash transaction valued at approximately US$270 million, paying US$4.00 per share.

This acquisition, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2025, pending regulatory clearance, successful completion of a tender offer, and other customary closing conditions.

This strategic move will significantly enhance BioMarin’s enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy currently being developed to treat ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency.

ENPP1 deficiency is a rare, progressive genetic disorder that adversely affects blood vessels, bones, and soft tissues.

It carries a high risk of cardiovascular mortality, especially in infants, and causes severe skeletal issues such as rickets and osteomalacia in both children and adults.

The first pivotal Phase III trial data for INZ-701 in pediatric patients is anticipated in early 2026, with potential regulatory approval expected in 2027.

BioMarin plans to initiate a cash tender offer to purchase all outstanding shares of Inozyme common stock.

The Inozyme board has unanimously recommended that shareholders tender their shares.

Following the tender offer, a BioMarin subsidiary will merge with Inozyme, converting any remaining shares into the right to receive the same US$4.00 per share in cash. The acquisition is not dependent on external financing.

Alexander Hardy, BioMarin’s President and CEO, emphasized the significance of this acquisition, stating that it aligns with BioMarin’s long-standing commitment to advancing enzyme therapies for serious genetic conditions affecting both children and adults.

He noted that INZ-701 has the potential to become the first treatment available for patients with ENPP1 deficiency, thereby improving care for those living with this serious condition.

Hardy also highlighted BioMarin’s strategy to continue evaluating both external and internal innovations to accelerate the development of medicines addressing significant unmet medical needs.

This acquisition complements BioMarin’s existing enzyme therapy portfolio, which recently saw an expansion when the US Food and Drug Administration approved an expanded use of BioMarin’s Brineura therapy for children under three years with neuronal ceroid lipofuscinosis type 2 (CLN2) disease.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.